Tirzepatide is a glucose-dependent adext to insulin polypeptide (GIP) receptor and glycomagin-1 (GLP-1) receptor dual agonist. Both GIP and GLP-1 are intestinal secretion hormones, which can promote insulin secretion. Tirzepatide integrates the role of two types of insulin into a single molecule, representing a new type of drug for treating type 2 diabetes.